IQCH Inhibitors
IQCH inhibitors are a category of chemical compounds designed to specifically hinder the activity of the IQ motif-containing protein H (IQCH), which plays a crucial role in cellular processes. These inhibitors are characterized by their ability to bind to the active or allosteric sites of IQCH, thereby modulating its function. IQCH is an integral part of signaling pathways that regulate various aspects of cellular physiology, including cytoskeletal organization and intracellular transport. By targeting IQCH, these inhibitors can influence the behavior of cells and are valuable tools for dissecting the biological role of this protein.
The design of IQCH inhibitors is often informed by the three-dimensional structure of the protein, enabling the creation of molecules that fit precisely within its active site or interact with regions critical for its conformational stability. The specificity of these inhibitors is paramount to ensure minimal off-target effects on other proteins. By preventing the normal function of IQCH, these compounds can elucidate the pathways in which this protein is involved. The inhibition usually results from blocking the protein's ability to interact with other molecules or from stabilizing it in an inactive conformation. This approach allows researchers to study the downstream effects of IQCH inhibition, shedding light on the protein's role in cellular signaling networks and its contribution to maintaining homeostasis within the cell.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that can indirectly inhibit the function of IQCH by affecting kinase-dependent signaling pathways, which IQCH may be reliant upon for its proper localization or function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. Since PI3K signaling is crucial for many cellular processes, its inhibition can lead to a cascade of effects that may include the alteration of the cytoskeletal dynamics, potentially affecting IQCH's role in cytoskeletal organization. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin), which is a central molecule in regulating cell growth and metabolism. Through this inhibition, it could indirectly affect IQCH function by altering cellular growth signals that IQCH may be involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting this pathway, there can be an indirect effect on IQCH if it is involved in signaling cascades related to cell proliferation and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is involved in stress responses, and its inhibition could affect IQCH if it plays a role in cellular responses to stress or inflammation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in apoptotic processes. Inhibition of this pathway can lead to changes in cell survival mechanisms and might indirectly impact IQCH if it is involved in apoptotic signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor, which, like PD98059, can inhibit the MAPK/ERK pathway, potentially affecting IQCH's function if it is linked to this pathway for cell proliferation and differentiation signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, it can lead to a broad range of intracellular effects, potentially impacting IQCH's function in processes like vesicular trafficking or cytoskeletal arrangement. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor. If IQCH is involved in pathways downstream of EGFR, such as those regulating cell division or apoptosis, its function could be indirectly inhibited by blocking EGFR signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, specifically inhibiting BCR-ABL, c-Kit, and PDGFR. If IQCH interacts with or is regulated by pathways involving these kinases, its activity could be affected by imatinib. | ||||||